13 January 2015: advert for Zaluron XL tablets
Published 14 April 2015
© Crown copyright 2015
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-january-2015/13-january-2015-advert-for-zaluron-xl-tablets
The Prescription Medicines Code of Practice Authority passed an anonymous complaint to MHRA. The complainant alleged that an email alert sent by Fontus Health Limited to healthcare professionals about Zaluron XL Tablets (quetiapine) promoted unlicensed medicines.
MHRA did not uphold the complaint and found the email focused on the cost of the product. This was sent to medicines management teams in clinical commissioning groups and Fontus Health demonstrated how the price of their new product would differ from the prices of equivalent products available.